Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 925485, 9 pages
Review Article

Prevention and Restoration of Hearing Loss Associated with the Use of Cisplatin

1Otolaryngology Department, Military Hospital Cluj-Napoca, 22 General Traian Mosoiu Street, 3400 Cluj-Napoca, Romania
2II-nd Department of Otolaryngology, Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca, Strada Republicii 18, 400015 Cluj-Napoca, Romania

Received 2 May 2014; Accepted 10 July 2014; Published 22 July 2014

Academic Editor: Srdjan Vlajkovic

Copyright © 2014 Felician Chirtes and Silviu Albu. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. Cisplatin is a well known platinum-based chemotherapeutic agent used for the treatment of various malignant tumours. A frequent side effect of cisplatin therapy is ototoxicity. Unfortunately, currently there are no available treatments. Material and Methods. Experimental, clinical studies and reviews published between 2004 and 2014 in the English medical literature concerning ototoxicity were selected using Medline, PubMed, and Google Scholar databases. Inclusion criteria were cisplatin-induced ototoxicity and therapy aimed at preventing or curing this disorder. Molecular mechanisms and clinical, audiological, and histological markers of cisplatin-induced ototoxicity are described. Moreover, experimental and clinical strategies for prevention or treatment of hearing loss were also reviewed. Results and Discussion. Experimental studies demonstrate a wide range of otoprotective molecules and strategies efficient against cisplatin-induced hearing loss. However, only dexamethasone proved a slight otoprotective effect in a clinical study. Conclusion. Further research must be completed to bring future therapeutic options into clinical setting.